Clinical AI Intelligence · GTM & Product
Your competitive landscape,
Abridge
Revenue-driving competitive intelligence across 7 companies. Dragon Copilot, Suki AI, Augmedix/Commure, DeepScribe, Nabla, Freed AI — 2026 signals only. Updated Apr 6, 2026.
Live · Q2 2026
caelian://abridge · clinical-ai · competitive-intel · 2026
7 companies · 38 signals · updated Apr 6 2026
In this report
01Intelligence → Actions 02Pricing Intelligence 03Action Items by Team ✦ 04Product Gap Analysis ✦ 05Abridge vs. Field Matrix ✦ 06Weekly Signal Digest ✦
The Core Framework
Intelligence → Insights → Actions
Every key competitive signal mapped to a strategic insight and a specific revenue move. Sorted by urgency.
P1
📡 Intelligence
Dragon Copilot rebrand + Nuance layoffs (Feb 2026). Microsoft consolidating healthcare AI. 100K+ daily clinicians across 600+ health systems but internal disruption signal underway.
💡 Insight
Nuance enterprise customers are navigating a platform change mid-transition. Procurement teams at Nuance-heavy health systems are re-evaluating vendors — especially those on Q2–Q3 renewal cycles.
⚡ Action
Launch "Nuance displacement" campaign now. Champion single-focus clinical AI vs. Microsoft bundle. Lead with KLAS #1 2026 as the proof of independence advantage.
MarketingBD
P1
📡 Intelligence
Augmedix/Commure: HCA Healthcare exclusive (40M+ appointments) + Vizient GPO contract giving access to 65% of US acute care without a standard RFP process.
💡 Insight
Commure bundles ambient + autonomous coding + charge capture + RCM into one contract. GPO listing removes the friction that protects Abridge's enterprise sales cycle.
⚡ Action
Explore Vizient / Premier GPO listing. Accelerate Abridge + Availity "ambient-to-billing" positioning. Build TCO comparison vs. Commure Pro's monolithic stack.
BDExec
P1
📡 Intelligence
Suki launches Ambient Orders Staging (Apr 2025, industry first) + becomes athenahealth Preferred Partner (Jan 2026) — ~160K warm pipeline providers now default to Suki in athenahealth deals.
💡 Insight
Orders staging is Suki's #1 differentiator in head-to-head pitches. Preferred status locks Suki into athenahealth's GTM — a channel Abridge currently doesn't have.
⚡ Action
Announce Abridge orders roadmap GA date this quarter. Pursue athenahealth preferred partner status before the channel fully closes to competition.
ProductBD
P1
📡 Intelligence
Nabla partners with Yann LeCun's AMI Labs ($1B startup, Mar 2026) + launches Nabla Connect SDK (Oct 2025) — any EHR can embed Nabla ambient AI in days without an enterprise deal.
💡 Insight
Connect creates B2B2C distribution that bypasses enterprise sales entirely. AMI Labs is a PR weapon even before the product ships — "world model AI" will appear in every pitch deck.
⚡ Action
Publish Abridge's agentic AI roadmap milestones now. Brief prospects on pre-commercial AI research risk vs. KLAS-validated clinical AI. Don't let Nabla win the "next-gen AI" narrative.
MarketingProduct
P1
📡 Intelligence
DeepScribe on track for 3.1M cancer visits/year (Nov 2025) — exclusive distribution in Flatiron OncoEMR (4,200 providers) and Ontada iKnowMed. Monthly oncology volume 4x'd since Jan 2025.
💡 Insight
Oncology requires purpose-built AI: biomarkers, treatment plans, trial matching, regimen notation. Generic scribing tools lose on clinical specificity. This vertical is closing to new entrants.
⚡ Action
Build oncology-specific note templates for top 10 cancer types or partner with Varian/MOSAIQ/ION before DeepScribe locks the oncology EHR distribution layer entirely.
ProductBD
P1
📡 Intelligence
Epic announces competing AI products (Aug 2025). Abridge CEO issued public reassurance. Best in KLAS 2026 #1 is the near-term shield. Risk highest in sub-500-bed Epic facilities.
💡 Insight
Epic's AI won't displace existing Abridge logos in 2026. But it creates a headwind in new pipeline — especially with smaller health systems lacking dedicated IT procurement.
⚡ Action
Arm all AEs with 3-point Epic counter: (1) KLAS #1 vs. Epic's unrated tool, (2) 55+ specialty depth, (3) prior auth via Availity — a workflow Epic cannot replicate natively.
BDExec
P2
📡 Intelligence
Freed AI: Sequoia $30M Series A, 25K+ clinicians, $39–$119/mo D2C. AI Receptionist + RCM entering Early Access Mar 2026. 47% of US clinicians are in independent practice — Abridge's blind spot.
💡 Insight
Freed creates "shadow IT" inside health systems — clinicians use Freed personally even when their hospital uses Abridge. RCM expansion signals upmarket ambition within 18 months.
⚡ Action
Create a "Freed vs. Abridge for health systems" page covering compliance, Epic SSO, clinical AI depth, and the data governance risk of unsanctioned tools at scale.
Marketing
P2
📡 Intelligence
Dragon Copilot ~$600/mo · Suki $299–399/mo · Abridge ~$208/mo · Nabla $119/mo · Freed $39/mo. A five-tier pricing stack with no clear mid-market player at $150–250/mo.
💡 Insight
Abridge is price-competitive at enterprise volume but has zero self-serve. Dragon Copilot's ~3x premium creates a clear wedge in pitches with 200–1,000 provider health systems.
⚡ Action
Build a "Microsoft tax" comparison slide showing total Dragon Copilot TCO vs. Abridge. Publish ROI framework showing time savings, coding accuracy, and PA reduction in dollar terms.
MarketingBD
P2
📡 Intelligence
Nabla (Paris HQ, GDPR-native) + Dragon Copilot EU rollout (Oct 2025). European ambient AI market opening. Abridge has no public EU data residency or GDPR compliance.
💡 Insight
European demand is real and growing. Nabla has a 2-year head start with GDPR-native architecture. Microsoft has Azure EU infrastructure. Abridge's GDPR gap blocks every EU enterprise deal today.
⚡ Action
Scope EU data residency + GDPR compliance timeline this half. Even a roadmap signal protects the brand in UK/Canada/EU prospects. Don't cede "global ambient AI" to Nabla.
ProductExec
P2
📡 Intelligence
Abridge: $800M raised, $5.3B valuation, $100M+ ARR, 250+ health systems, KLAS #1 2025 + 2026. Undisputed category leader — and increasingly perceived as such by smaller buyers.
💡 Insight
Scale creates "too expensive / over-engineered" perception in sub-200 provider health systems. The same brand that wins large enterprise deals creates hesitation in mid-tier procurement.
⚡ Action
Publish the $100M ARR milestone across all sales assets. Build a "why Abridge" page addressing competitor claims directly. Lead with CMU/UPMC research depth, not just feature lists.
Marketing
Pricing Intelligence
What the market is charging
Per-provider monthly pricing across all 7 companies. Abridge's enterprise-only model is both a GTM risk and a positioning opportunity.
$208
ABRIDGE
$600+
DRAGON
Custom
AUGMEDIX
$299
SUKI
$350
DEEPSCRIBE
$119
NABLA
$39
FREED
Dimension Abridge Dragon Copilot Augmedix Suki AI DeepScribe Nabla Freed AI
Pricing & Access
Entry price / mo ~$208 enterprise ~$600+ opaque Custom enterprise $299 listed ~$350 custom $119 listed $39 listed
Self-serve signup No No No No No No Yes
Free trial No No No No No No 7-day
Feature Differentiation
E&M / ICD-10 coding ✓ included via partners ✓ Commure add-on ✓ included roadmap Premier only
Prior authorization ✓ Availity via partners via Commure No No No No
Ambient orders staging TBD No No ✓ Apr 2025 No roadmap No
Human scribe option No No ✓ Go/Assist/Live No No No No
Languages 28 English + EU English 80+ English 35+ English +
GTM & Distribution
Primary segment Enterprise health systems Enterprise (Epic/athena) Enterprise + GPO Mid-market + enterprise Oncology specialty Mid-market Independent practice
Distribution channel Direct + Epic embed Microsoft + EHR embed Direct + Vizient GPO Direct + EHR partner Direct + oncology EHR Direct + Connect SDK D2C self-serve
Abridge Edge
Most price-competitive enterprise platform at scale. At 500 providers, Abridge saves ~$2M/year vs. Dragon Copilot.
Blind Spot
Zero self-serve = 0% capture of independent practice (47% of US clinicians). Freed owns this segment entirely.
Immediate Action
Publish ROI calculator + "Microsoft tax" slide. Frame Availity prior auth as the feature no competitor at any price point offers.
03 P1 · P2 · P3 Action Items by Team 21 items
P1 · DO THIS WEEK · 8 items
Activate Nuance displacement playbook
Target 120+ DAX renewal accounts in Q2 with a structured outbound sequence. Microsoft layoffs create relationship uncertainty at every customer site. Your KLAS #1 2026 win is the key message.
BDMarketing
Announce orders staging roadmap date
Suki owns this feature first. Brief your top 50 enterprise accounts with your GA timeline before Suki uses the feature gap in an active renewal or competitive RFP.
Product
Deploy Availity + prior auth messaging
No other ambient AI player offers prior auth at point of care. This is your only unique RCM differentiator vs. every competitor. Make it the lead message in every Q2 enterprise pitch deck.
Respond to Epic AI noise with data
Create a "Abridge vs. Epic AI" one-pager with 3 data points: KLAS #1 (rated) vs. Epic (unrated), 55+ specialty coverage, prior auth via Availity. Arm every AE with this before their next pitch.
P2 · THIS QUARTER · 9 items
Pursue athenahealth preferred partner status
Suki won Preferred Partner in Jan 2026 and gets co-sell from athenahealth's own sales team. You need at minimum a certified partner listing to prevent Suki from owning ~160K warm providers exclusively.
Explore Vizient + Premier GPO contracts
Augmedix/Commure's Vizient contract gives access to 65% of US acute care without an RFP. Evaluate both Vizient and Premier Health Alliance group purchasing contracts to unlock the same channel economics.
Build "Microsoft tax" enterprise slide
At 500 providers, Dragon Copilot costs ~$4.3M/year vs. Abridge ~$1.25M. Build a single slide showing per-seat + Azure overhead + integration cost. This closes 30%+ of Dragon Copilot competitive deals.
Develop payer-sponsored ambient playbook
Highmark Health co-funds Abridge deployment for payer benefit. This model — where the payer pays for ambient AI at health system partners — is replicable across Blues affiliates and ACO participants.
P3 · THIS HALF · 4 items
Invest in oncology vertical AI
DeepScribe is on track for 3.1M cancer visits/year with exclusive Flatiron + Ontada distribution. Build oncology-specific note templates for the top 10 cancer types or partner with Varian/MOSAIQ/ION before this vertical closes permanently.
Scope EU data residency + GDPR roadmap
Nabla (GDPR-native, Paris HQ) and Dragon Copilot (EU live since Oct 2025) are capturing European health systems. Abridge's GDPR gap blocks every EU + UK enterprise deal today. Even a roadmap signal protects the brand.
Build MEDITECH integration path
Suki is the first ambient AI in MEDITECH Expanse. MEDITECH serves ~25% of US hospitals (primarily rural and community). Without an integration path, Abridge has no story for this segment.
04 Product Gap Analysis 6 gaps identified
Ambient Orders StagingCRITICAL
Suki launched industry-first in Apr 2025. Abridge has no GA date. In every head-to-head deal where orders staging is a requirement, Suki wins. This is the #1 product gap by sales impact.
Who has it: Suki · Nabla (roadmap)
Oncology-Specific AI ModelHIGH
DeepScribe has a purpose-built oncology model covering biomarkers, treatment plans, and trial matching. Abridge's general model loses every oncology-specific deal to DeepScribe.
Who has it: DeepScribe (exclusive)
Human Scribe Hybrid TierMEDIUM
Augmedix offers Go/Assist/Live tiers — pure AI through fully human-assisted. Risk-averse health systems can start with human oversight and migrate. Abridge offers no equivalent trust bridge.
Who has it: Augmedix/Commure only
EHR-Agnostic SDK / White-LabelHIGH
Nabla Connect SDK lets any EHR embed Nabla ambient AI in days. This creates B2B2C distribution that bypasses Abridge's enterprise sales cycle entirely. No equivalent Abridge offering exists.
Who has it: Nabla (Nabla Connect)
EU / Global Data ResidencyMEDIUM
GDPR-native infrastructure is table stakes for European health systems. Nabla (Paris HQ) and Dragon Copilot (Azure EU live) have this. Abridge's GDPR gap blocks every EU, UK, and Canada enterprise deal.
Who has it: Nabla · Dragon Copilot
Self-Serve / SMB Entry TierMEDIUM
47% of US clinicians are in independent practices. Freed captures this segment at $39/mo self-serve with no sales cycle. Abridge's enterprise-only motion has zero surface area in this market.
Who has it: Freed AI · Nabla ($119)
05 Abridge vs. the Field — Full Matrix
Abridge
Dragon
Augmedix
Suki
DeepScribe
Nabla
Freed
KLAS ranking
#1 2026
Not listed
Top 20
Preferred
98.8 score
Emerging
Not listed
Clinician users
250+ HS
100K+ daily
40M appts
350+ HS
2,800+ clinics
85K+ clinicians
25K+ clinicians
Prior auth
✓ Availity
Partners
Commure
✗
✗
✗
✗
21 ACTION ITEMS
6 PRODUCT GAPS
FULL 7-CO MATRIX
WEEKLY UPDATES
3 market windows are closing this quarter.
Your competitors already know.
The full report includes P1/P2/P3 action items by team, 6 identified product gaps, a complete Abridge vs. the field matrix, and weekly signal updates — built for GTM and product leaders.
Book a 15-min Call to Unlock →
Free call · No commitment · Delivered same day